CV Lattes
ResearcherID
ORCID
Universidade de São Paulo (USP). Faculdade de Medicina de Ribeirão Preto (FMRP) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Dr. Colli is graduated in Medicine from Universidade de São Paulo (USP) in 2007, received his Ph.D. in Medical Sciences from Universidade de São Paulo in 2012, and was Medical Oncology Fellow until 2014 at Ribeirao Preto University Hospital (USP). He was Postdoc at National Cancer Institute (NIH) between 2013 and 2019. Currently, Dr. Colli is Assistant Professor of Medical Oncology Ribeirão Preto Medical School (USP) and Head of the Medical Oncology Service. Main research interest on molecular oncology, genitourinary cancers (mainly renal cancer), cancer germline susceptibility, immunotherapy, biomarkers, and computational clinical oncology. It was awarded with the Royal Society-Newton Advanced Fellowship in 2020. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Genome-wide association studies (GWAS) are an important tool for the characterization of the genetic architecture of cancer susceptibility, and a key step towards understanding the process of cancer development. Each susceptibility region explains only a small fraction of cancer risk, but the aggregation of those regions allows us to understand a significant part of the heritability, usin…
Genome-wide association studies (GWAS) are an important tool for the characterization of the genetic architecture of cancer susceptibility, and a key step towards understanding the process of cancer development. Each susceptibility region explains only a small fraction of cancer risk, but the aggregation of those regions allows us to understand a significant part of the heritability, usin…
Renal cancer is the seventh most common type of cancer and shows a growing increase in the number of new cases, especially in Brazil. GWAS (Genome-Wide Association Study) studies have been applied to identify single nucleotide polymorphisms (SNPs) in chromosomal regions at risk for the development of this disease. From such studies, 13 different risk regions have been identified for renal…
Renal cell carcinoma (RCC) represents 2 to 3% of cancers worldwide, and is among the top ten most diagnosed, with a higher incidence in Western Countries. Among these, clear cell renal carcinoma (CCRcc) is the predominant histology seen, corresponding to 85% of cases. Treatment is with targeted therapy against vascular endothelial growth factor (VEGF) and with new immunotherapeutic agents…
Cancer is one of the most common causes of death in the world. Renal Carcinoma (RCC) is one of the ten main frequent types of Cancer, with an increasing number of new cases. Clear Cell Renal Carcinoma (ccRCC) is the most frequent subtype, responsible for about 75% of the cases. GWAS (Genome-Wide Association Study) is used for germline susceptibility discovery and has identified 13 regions…
Kidney cancer is responsible for more than 400,000 new diagnoses and 175,000 deaths annually. The most common form of this cancer is the Renal Cell Carcinoma - RCC-, which comprises a heterogeneous group of tumors originated by the epithelial cells of the renal tubules, the main subtype being the Clear Cell Carcinoma - ccRCC. The treatment of the RCC has undergone major changes over the p…
Renal cancer is among the 10 most incident carcinomas in the world, with about 403,000 new cases diagnosed in 2018. Recent studies have indicated an increase in the incidence of renal cancer in Brazil. Genome wide association studies (GWAS) are applied to identify single nucleotide polymorphisms (SNPs) in chromosomal regions at risk for the development of phenotypes such as cancer. From t…
Kidney cancer currently affects approximately 270,000 people worldwide. The knowledge about the molecular biology of this tumor allowed the development of tyrosine kinase inhibitory agents. The treatment of metastatic tumors with these inhibitors increases the overall survival of kidney cancer patients. However, there are important therapy-related adverse effects that decrease the patient…
(Only some records are available in English at this moment)
| 2 / 2 | Ongoing research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 7 / 6 | Completed scholarships in Brazil |
| 12 / 11 | All research grants and scholarships |
| Associated processes | |